Press ESC to close

DCGI gives approval for human clinical trials of COVAXIN

Pharma Admission

Pharma courses

pharma admission

pharma courses

Drug Controller General of India (DCGI) has given approval for human clinical trials of COVAXIN, the first potential COVID-19 Vaccine developed in India. The potential vaccine has been developed by Hyderabad-based Bharat Biotech, in association with Indian Council for Medical Research (ICMR). Human Trials for Phase I and Phase II are scheduled to start across the country from next month.

COVAXIN is an inactivated vaccine, created from a strain of the infectious SARS-CoV-2 virus. It has shown promising results in the pre-clinical studies demonstrating extensive safety and effective immune responses.

Drug manufacturers and research consortiums around the world are working towards development of a vaccine against the novel coronavirus.

“The proactive support and guidance from CDSCO have enabled approvals to this project. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” said Chairman and Managing Director, Dr. Krishna Ella.

<< Back to Pharma News

Subscribe to News Alerts by Email

Latest News

Leave a Reply